Less than three months after Spectrum Pharmaceuticals Inc. and Cell Therapeutics Inc. teamed up in a 50-50 joint venture to market the radioimmunotherapy drug Zevalin ([90Y]-ibritumomab tiuxetan), Spectrum is taking control of the compound. (BioWorld Today) Read More
